BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

...mRNA to encode therapeutic mAbs that are secreted in vivo . Two programs, BNT141 and BNT142...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies 2H20. BNT141 is an IgG antibody targeting undisclosed antigens on multiple solid tumor types. BNT142...
Items per page:
1 - 2 of 2